IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of “Moderate Buy” by Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been assigned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $53.67.

A number of brokerages recently commented on IDYA. Leerink Partners lowered IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and cut their target price for the company from $41.00 to $27.00 in a research note on Tuesday, November 5th. Leerink Partnrs lowered IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Oppenheimer restated an “outperform” rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Citigroup lowered their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday, August 27th. Finally, Stifel Nicolaus raised their target price on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th.

IDEAYA Biosciences Trading Down 2.3 %

IDYA opened at $25.19 on Monday. IDEAYA Biosciences has a 1-year low of $24.72 and a 1-year high of $47.74. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -10.81 and a beta of 0.79. The business has a 50 day moving average of $28.73 and a 200-day moving average of $34.37.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period last year, the business earned ($0.46) earnings per share. Equities analysts predict that IDEAYA Biosciences will post -2.45 EPS for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

Institutional investors have recently modified their holdings of the business. KBC Group NV raised its position in IDEAYA Biosciences by 29.1% in the 3rd quarter. KBC Group NV now owns 2,274 shares of the company’s stock valued at $72,000 after buying an additional 513 shares during the last quarter. Amalgamated Bank raised its position in IDEAYA Biosciences by 22.9% in the 3rd quarter. Amalgamated Bank now owns 2,840 shares of the company’s stock valued at $90,000 after buying an additional 530 shares during the last quarter. US Bancorp DE raised its position in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after buying an additional 689 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of IDEAYA Biosciences by 35.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock worth $94,000 after purchasing an additional 796 shares during the last quarter. Finally, Allworth Financial LP increased its position in shares of IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 800 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.